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Guy T’Sjoen3
Metabolomic analyses in epidemiological studies have demonstrated a strong sexual dimorphism for 
most metabolites. Cross-sex hormone treatment (CSH) in transgender individuals enables the study of 
metabolites in a cross-gender setting. Targeted metabolomic profiling of serum of fasting transmen and 
transwomen at baseline and following 12 months of CSH (N = 20/group) was performed. Changes in 186 
serum metabolites and metabolite ratios were determined by targeted metabolomics analysis based 
on ESI-LC-MS/MS. RandomForest (RF) analysis was applied to detect metabolites of highest interest 
for grouping of transwomen and transmen before and after initiation of CSH. Principal component 
analysis (PCA) was performed to check whether group differentiation was achievable according to these 
variables and to see if changes in metabolite levels could be explained by a priori gender differences. 
PCA predicted grouping of individuals-determined by the citrulline/arginine-ratio and the amino acids 
lysine, alanine and asymmetric dimethylarginine - in addition to the expected grouping due to changes 
in sex steroids and body composition. The fact that most of the investigated metabolites did, however, 
not change, indicates that the majority of sex dependent differences in metabolites reported in the 
literature before may primarily not be attributable to sex hormones but to other gender-differences.
Transgender individuals are characterized by incongruence between gender identity and external sexual anatomy 
at birth. An etiological reason for this phenomenon has not been identified so far, but psychological and bio-
logical factors have been discussed in this context1–4. To mitigate the feeling of gender dysphoria, interventions 
such as cross-sex hormone treatment (CSH) and gender affirming surgeries (GAS) are applied in medical care of 
transgender persons.
Many diseases, such as autoimmune5, psychiatric6 or cardiovascular diseases7, show a sexual dimorphism 
with respect to prevalence rates. The underlying reasons are not completely understood but it is anticipated that 
there are multifactorial explanations for these findings5–8. In addition to the different genetic and psychosocial 
background of men and women7, sex steroids are suggested to have a significant effect on these outcomes9–11. CSH 
in transgender persons enables, to some extent, the study of the role of sex steroids in disease pathophysiology 
partially uncoupled from other sex-specific influential factors.
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With regard to metabolism, it is already known that CSH results in impressive changes in the physical appear-
ance towards the target-sex12,13 as well as in classical cardiovascular risk factors, such as the HDL-/LDL choles-
terol ratio, triglycerides12, fasting insulin levels, blood pressure14 or arterial stiffness15.
One technique that may shed light on so far unrevealed metabolic changes following the initiation of CSH is 
metabolomics. Metabolomics analyzes small molecules (or metabolites) of 80–1200 Da molecular mass in a bio-
logical sample16. The metabolome represents all metabolites regarded as the ultimate product resulting from the 
cascade of gene, mRNA and protein expression. Metabolites are considered as close proxies to the corresponding 
phenotype17. Although sex hormones are known to exert a variety of effects on metabolism18, this technique has 
rarely been used in this context19,20 so far, though it might provide a lot more information on altered metabolic 
processes than those provided by conventional laboratory analyses.
Interestingly, it has been demonstrated in epidemiological samples that the majority of metabolites meas-
ured seem to be differentially regulated between men and women21. In a large population-based epidemiolog-
ical study with more than 3000 participants, more than 101 out of the 131 investigated metabolites presented a 
sex-dependent dimorphism22. To what extent these differences can be attributed to a genetic basis or to the dif-
ferent sex hormonal milieu has not yet been investigated. Applying this technique to a sample of transgender per-
sons before and after initiation of CSH treatment may hence shed light on the general sex-hormone-accountable 
effect of sex-specific metabolite levels. In the following, we are therefore reporting the results of a prospec-
tive study in transgender persons investigating the effects of the initiation of CSH treatment by applying a 
targeted-metabolomics approach.
Materials and Methods
Patient population. Subjects investigated in this study were part of the European Network for the 
Investigation of Gender Incongruence (ENIGI), a collaboration of four European gender identity clinics 
(Amsterdam, Ghent, Hamburg, and Oslo) for the study of the diagnostics and treatment of transsexualism12.
All participants in this study had been diagnosed and treated at the Department of Endocrinology at Ghent 
University Hospital between February 2010 and August 2012. In total N = 20 Caucasian individuals per group 
were investigated at baseline and following 12 months of CSH treatment. All transwomen (MtF) were hormone 
naïve at baseline, while N = 6 transmen (FtM) had already received 5 mg Lynestrenol/d (Orgametril) in order 
to stop their menstrual cycle. All FtM were put on cross-sex hormone treatment with 1000 mg Testosterone (T) 
–undecanoate (Nebido, Jenapharm) every three months. The most appropriate mode of hormone treatment in 
MtF was chosen depending on the age of the corresponding subject, in view of the increased cardiovascular risk 
profile in older MtF. MtF below the age of 45 years (N = 13) were treated with 50 mg of Cyproteronacetat (CA) 
(Androcur, Bayer) in addition to 4 mg of estradiol valerate (EV) (Progynova, Bayer), both given orally once a day, 
while those being older than 45 years received 50 mg of CA daily and a transdermal 17-β -estradiol (E2) patch 
releasing 100 μ g/24 hours (Dermestril, Besins, Belgium) (N = 7).
This study was approved by the ethical review board of the Ghent University Hospital and the University 
Hospital of Oslo. The study was conducted in accordance with the Declaration of Helsinki and all participants 
gave written informed consent. This study is registered at clinical trials.gov. Clinical trial number: NCT01072825.
Medical History and Examination. Data on comorbidities and life-style, including smoking history, alco-
hol intake, medical history and medication use, were acquired from each patient by means of questionnaires 
and corresponding information was compared to the clinical information from the clinical data collected in the 
medical chart files. Physical activity was measured using the Baecke habitual physical activity questionnaire23.
Anthropometrics and laboratory measures. Assessments of anthropometry and laboratory meas-
urements have already been described elsewhere12. Briefly, height was measured to the nearest 0.1 cm using a 
Harpendenstadiometer (HoltainLtd, Crymuch, UK) and body weight was measured in light indoor clothing with-
out shoes to the nearest 0.5 kg. Body composition was assessed by means of dual-energy X ray absorptiometry 
with a Hologic Discovery Machine (Hologic Inc., Bedford, MA, USA). Serum samples were taken in the morning 
between 8:00 and 9:00 a.m. following an overnight fast. After a clotting period of 30–60 minutes, serum was 
immediately centrifuged and stored at − 80 °C until further analysis. 17-β -Estradiol (E2) and testosterone were 
determined using liquid chromatography tandem mass spectrometry (AB Sciex 5,500 triplequadrupole mass 
spectrometer; AB Sciex, Toronto, Canada). Immunoassays were used to determine follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), leptin and sex hormone binding globulin (SHBG) and interassay-coefficients 
of variance (CVs), please see ref. 12.
Targeted metabolomics. The targeted metabolomics approach was based on ESI-LC-MS/MS measure-
ments by AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). The assay allows simulta-
neous quantification of 188 metabolites out of 10 μ L plasma and includes free carnitine, 39 acylcarnitines (Cx:y), 
21 amino acids (19 proteinogenic + citrulline + ornithine), 21 biogenic amines, hexoses (sum of hexoses – about 
90–95% glucose), 90 glycerophospholipids (14 lysophosphatidylcholines (lysoPC) and 76 phosphatidylcholines 
(PC)) and 15 sphingolipids (SMx:y). The abbreviations Cx:y are used to describe the total number of carbons 
and double bonds of all chains, respectively (for more details, see ref. 24). The method of AbsoluteIDQ p180 
Kit has been proven to be in conformance with FDA-Guideline “Guidance for Industry-Bioanalytical Method 
Validation25, which implies proof of reproducibility within a given error range. Measurements were performed 
as described in the manufacturer in manual UM-P180. The LLOQ and ULOQ were determined experimentally 
by Biocrates.
Assay procedures of the AbsoluteIDQ p180 Kit have been described in detail previously24,26. Metabolite 
nomenclature can be found in the supplements (Supplementary Table 1).
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Sample handling was performed by a Hamilton Microlab STAR robot (Hamilton Bonaduz AG, Bonaduz, 
Switzerland) and an Ultravap nitrogen evaporator (Porvair Sciences, Leatherhead, U.K.), in addition to stand-
ard laboratory equipment. Mass spectrometric (MS) analyses were done on an API 4000 LC/MS/MS System 
(Sciex Deutschland GmbH, Darmstadt, Germany) equipped with a 1200 Series HPLC (Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and a HTC PAL auto sampler (CTC Analytics, Zwingen, Switzerland) 
controlled by the software Analyst 1.5.1. Data evaluation for quantification of metabolite concentrations and 
quality assessment was performed with the MetIDQ software package, an integral part of the AbsoluteIDQ Kit. 
Internal standards served as reference for the calculation of metabolite concentrations [μ M].
Statistical analysis. Data were analyzed using R software, v.3.1.2. Descriptive statistics were expressed as 
means and standard deviations. Statistical analyses of categorical variables were carried out using the χ 2-test. 
Statistics of means in prospective data were carried out using the paired student t-test for continuous variables. 
QQ plots were used to assess normality of distribution. McNemar’s test was used for dichotomous variables. 
Significance was set at the p < 0.05 level (two-tailed). To select the most interesting metabolites for Principal 
Component Analysis (PCA) plotting, a randomforest (RF) analysis was performed27 in R28.
Results
General characteristics. Transwomen (MtF). Twelve months of CSH resulted in significant changes in 
terms of body composition. While there was no change in anthropometric measures, such as weight or BMI, CSH 
led to a significant decrease in the percentage of lean body mass and corresponding increase in relative fat mass 
(p < 0.001). Induction of hormonal therapy did not seem to significantly change any life-style variables, including 
smoking behavior, physical activity or alcohol intake. As intended, there were several significant changes in terms 
Antropometry
Mean (SD)
p-valueBaseline 12 months follow-up
BMI (kg/m2) 23.90 (4.34) 24.28 (4.01) 0.78
Weight (kg) 76.87 (15.45) 78.50 (14.68) 0.743
WTH-Ratio 0.89 (0.06) 0.86 (0.078) 0.11
Total lean mass (kg) 59.49 (10.65) 56.45 (10.02) 0.37
Total fat (%) 18.56 (4.46) 23.92 (3.64) < 0.001
Total lean mass (%) 78.1 (4.17) 72.71 (3.45) < 0.001
Total fat mass (kg) 14.65 (5.76) 18.86 (5.36) 0.026
Grip-strength (kg) 41.71 (7.77) 41.88 (7.03) 0.948
Systolic blood pressure (mmHg) 127.44 (22.65) 123.06 (12.60) 0.482
Diastolic blood pressure (mmHg) 76.94 (13.12) 75.00 (8.83) 0.609
Life style
 Overall physical activity 8.17 (1.63) 8.36 (1.88) 0.736
 Current smoking 0.16 (0.37) 0.16 (0.37) 1
 Alcohol intake/week (glasses) 2.32 (2.93) 1.95 (3.19) 0.713
Lab measurements 
Hormones
 Estradiol (pg/ml 24.36 (7.11) 64.75 (32.93) < 0.001
 Total testosterone (ng/dl) 591.28 (162.67) 57.65 (131.78) < 0.001
 Free testosterone (nmol/l) 11.36 (3.46) 1.24 (2.98) < 0.001
 FSH (μ U/ml) 5.50 (4.14) 0.81 (1.44) < 0.001
 LH (μ U/ml) 5.58 (2.34) 0.75 (1.63) < 0.001
 SHBG (nmol/l) 39.07 (18.14) 44.40 (21.93) 0.425
 Leptin (μ g/l) 4.89 (4.14) 11.41 (5.24) < 0.001
Other
 Hematocrit (%) 45.21 (2.67) 42.73 (1.79) 0.002
 Total cholesterol (mg/dl) 185.47 (37.43) 166.26 (31.07) 0.094
 HDL (mg/dl) 53.95 (11.66) 56.84 (8.50) 0.039
 LDL (mg/dl) 112.99 (34.16) 103.10 (28.43) 0.339
 Triglycerides (mg/dl) 92.32 (52.66) 81.21 (27.47) 0.422
 Insulin (mIU/l) 7.67 (3.47) 12.84 (7.86) 0.018
 Fasting glucose (mg/dl) 87.63 (9.88) 87.06 (13.97) 0.886
 HOMA-Index 1.59 (0.87) 2.66 (1.85) 0.04
Table 1.  General characteristics of transwomen. BMI: body mass index; WTH: waist-to-hip; FSH: follicle-
stimulating hormone; LH luteinizing hormone HOMA: Homeostasis Model Assessment; HDL: high-density 
lipoprotein cholesterol LDL: low-density lipoprotein cholesterol.
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of hormone measurements. There was a significant increase in serum estradiol levels and a significant decrease 
in total and free testosterone levels (p < 0.001). As a result, hematocrit levels were decreased after 12 months of 
continuous CSH (p = 0.002). LH and FSH were significantly suppressed at follow-up (p < 0.001). CSH further 
resulted in a significant increase in leptin (p < 0.001) and insulin levels (p = 0.018). This caused a significant 
increase in HOMA index as a measure of insulin resistance (p = 0.040), while fasting glucose was not affected.
CSH further led to a significant increase in HDL levels (p = 0.039) but no changes in LDL or total cholesterol 
levels.
At baseline, those who received transdermal E2 in contrast to those receiving oral E2 only differed in terms of 
physical activity (p = 0.002) and free testosterone (p = 0.023), in accordance with the higher age of this subgroup. 
At follow-up, there was only a persisting difference in terms of physical activity in general and sport activity in 
particular (p = 0.036) between oral and transdermal E2 users. In particular, individuals did not differ in terms of 
other sex hormone levels or anthropometric measures (data not shown). Thus, they were regarded as only one 
group (Table 1) in the following analysis.
Transmen (FtM). Testosterone treatment did not affect BMI or weight but significantly increased lean mass 
(p = 0.030) in transmen. Total and free testosterone (T) levels were significantly higher at follow-up and estradiol 
levels significantly lower (p < 0.001). SHBG (p = 0.009) and leptin (p = 0.003) were both lower at follow-up. Any 
changes in terms of life-style variables were not observed. Fasting glucose as well as insulin levels remained unal-
tered as did lipid levels.
At baseline, there were significant differences in terms of BMI (p = 0.018) and weight (p = 0.020) between 
those with preceding progestin intake and those without, while there was no significant difference in terms of lean 
or total fat mass (Table 2). While E2 (p = 0.036) and SHBG (p = 0.007) levels were lower in those with Lynestrenol 
Antropometry
Mean (SD)
p-valueBaseline 12 months follow-up
BMI (kg/m2) 23.49 (4.55) 24.87 (3.65) 0.314
Weight (kg) 64.97 (14.19) 67.19 (12.45) 0.605
WTH-Ratio 0.80 (0.09) 0.80 (0.087) 0.905
Total lean mass (kg) 43.34 (7.24) 48.34 (6.21) 0.03
Total fat (%) 27.22 (6.98) 24.06 (6.13) 0.151
Total lean mass (%) 69.36 (6.68) 72.69 (5.87) 0.115
Total fat mass (kg) 17.90 (8.08) 16.63 (6.42) 0.6
Grip-strength (kg) 30.21 (7.25) 32.40 (6.09) 0.322
Systolic blood pressure (mmHg) 115.80 (13.64) 117.06 (14.90) 0.789
Diastolic blood pressure (mmHg) 74.80 (11.33) 45.94 (10.10) 0.967
Life style
 Overall physical activity 9.11 (2.25) 9.44 (2.72) 0.685
 Current smoking 0.30 (0.47) 0.20 (0.41) 0.478
 Alcohol intake/week (glasses) 0.55 (1.43) 1.55 (2.65) 0.147
Lab measurements
Hormones
 Estradiol (pg/ml) 80.69 (57.72) 27.36 (10.62) <0.001
 Total testosterone (ng/dl) 42.37 (55.24) 644.04 (253.08) <0.001
 Free testosterone (nmol/l) 0.77 (0.90) 14.98 (5.91) <0.001
 FSH (μ U/ml) 4.44 (2.13) 17.61 (31.36) 0.076
 LH (μ U/ml) 6.47 (6.39) 14.66 (27.19) 0.205
 SHBG (nmol/l) 57.68 (36.10) 33.19 (13.84) 0.009
 Leptin (μ g/l) 15.27 (10.63) 6.63 (4.53) 0.003
Other
 Hematocrit (%) 41.33 (2.93) 44.95 (3.24) <0.001
 Total cholesterol (mg/dl) 175.3 (31.79) 186.21 (37.38) 0.334
 HDL (mg/dl) 53.10 (13.90) 50.16 (10.10) 0.453
 LDL (mg/dl) 106.52 (30.39) 116.51 (32.32) 0.453
 Triglycerides (mg/dl) 77.95 (41.49) 102.32 (61.02) 0.157
 Insulin (mIU/l) 10.27 (6.64) 12.12 (9.60) 0.482
 Fasting Glucose (mg/dl) 80.50 (7.67) 80.25 (11.37) 0.936
 HOMA-Index 2.08 (1.43) 2.50 (2.34) 0.495
Table 2.  General characteristics of transmen. BMI: body mass index; WTH: waist-to-hip; FSH: follicle-
stimulating hormone; LH luteinizing hormone HOMA: Homeostasis Model Assessment; HDL: high-density 
lipoprotein cholesterol LDL: low-density lipoprotein cholesterol.
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pre-treatment, no significant differences could be observed regarding T and LH/FSH-levels. Leptin and insulin 
levels as well as lifestyle aspects remained stable.
At 12 months’ follow-up, FtM with Lynestrenol pretreatment only differed from those without in terms of 
lower total testosterone (p < 0.038) and lower SHBG levels (p = 0.009) but not in terms of free T (data not shown).
Metabolomics. A Chi square test was performed for the whole data set, the combination of physiological 
patient data and metabolite measurements. Results indicated that measured values and clinical data were not 
independent from one another.
Multivariate analysis and feature selection. RF was applied to detect metabolites with the highest influence for 
grouping of MtF and FtM patients. Results were then plotted as heatmaps (Fig. 1). Three patients were excluded 
from analysis due to insufficient data on body composition or sex steroid levels. As there was no clear division 
into groups possible at this level, principal component analysis (PCA) was performed to check whether differenti-
ation after RF was achievable (Fig. 2). This PCA predicted grouping of individuals highly depends on asymmetric 
dimethylarginine (ADMA), testosterone, estradiol, the citrulline/arginine-ratio, lysine and body composition. 
The outliers from the grouping were also most likely defined by metabolites in the northern area of the plot.
By studying the variables identified by RF in detail, a decrease in lysine in FtM was observed, while the oppo-
site was true for MtF. In contrast, there was an increase in alanine in FtM but a decrease in MtF. Following 12 
months of CSH, ADMA levels declined in FtM and remained stable in MtF. The strongest effect of CSH was 
observed for the citrulline/arginine-ratio for both sexes. The citrulline/arginine-ratio was increased in FtM and 
strongly decreased in MtF (Fig. 3a–d). While some metabolites tended to approach metabolite levels of the target 
sex in the course of treatment, the concentrations of metabolites remained stable in most cases (Fig. 4).
Discussion
We found that CSH over 12 months induced a variety of changes in metabolic pathways. As we were particularly 
interested in variables explaining a priori gender differences, we will focus the following discussion on metabo-
lites having been selected for group separation by RF.
Figure 1. Differentiation of patients by sex hormones, body composition and metabolites. Heatmap 
analysis shows strong influence of sex hormones administered by CSH. Minute changes in metabolite 
compositions are masked by the bigger effects of sex hormones involved in CSH. The metabolites shown here 
were selected by randomForest analysis. Cx:y: Acylcarnitines (The abbreviations Cx:y are used to describe the total 
number of carbons and double bonds of all chains). lysoPC: Lysophosphatidylcholines. PC: Phosphatidylcholines 
SMx:y: Sphingolipids M0: Baseline. M12: After 12 month of cross-sex hormone treatment.
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Metabolism of amino acids. We observed a decrease in alanine and lysine levels in transwomen and an 
increase in transmen. Free amino acid concentrations (AA) seem to be lower in women than in men in general29, 
and these findings are largely independent of anthropometric measures. In line with this, Burck et al. observed a 
decrease in several free AA in transwomen following CSH and an increase in transmen30. The interpretation of 
this finding is complex, as is AA metabolism.
Concentrations of free AA usually show relatively little inter- or intra-individual variation31,32 and are primar-
ily determined by the balance of release from endogenous protein stores and utilization by various tissues. In the 
fasted state, protein breakdown usually exceeds protein synthesis33 and free AA primarily reflects release rates 
from the splanchnic organs.
Alanine is the most abundant free AA32. Sources of alanine include the muscle, the gut and, to a lesser extent, 
the kidneys. Muscle mass accounts for 50% of the total body pool of free AA31. It is therefore tempting to ascribe 
the decrease in alanine and lysine in transwomen to the accompanying decrease in muscle mass. However, these 
AA have been identified as free fat mass-independent contributors for gender differences in our sample. Sex hor-
mones, especially testosterone, are known regulators of whole body and muscle protein turn-over34. Testosterone 
administration in men results in an increased protein synthesis and reutilization of intracellular AA in skeletal 
muscles, but not in changes in AA in- or efflux35. In line with this, Brodsky and colleagues did show that free AA 
do not significantly change following six months of testosterone supplementation in hypogonadal men despite 
an increase in muscle mass and protein synthesis36. So far, given the provided background, it may be justified to 
speculate that the observed AA changes in our sample are primarily determined by direct effects of sex hormones 
on AA release from the splanchnic region.
Arginine-Metabolism. In addition, a decrease in the citrulline/arginine-ratio in transwomen and an 
increase in transmen was observed. This finding was primarily driven by changes in citrulline, while there were 
no changes in arginine levels. In agreement with this Burk et al.30 observed a significant decrease in citrulline 
in transwomen and an increase in transmen, following CSH. The sex steroid dependency of these AA has also 
been demonstrated in samples of postmenopausal women receiving estrogen replacement therapy resulting in an 
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Figure 2. Group clustering by metabolites. This variable factor map of the most important metabolites, as 
selected by randomForest analysis, was drawn for the differentiation of MtF and FtM patient grouping. The 
grouping was calculated by PCA. Cx:y: Acylcarnitines (The abbreviations Cx:y are used to describe the total 
number of carbons and double bonds of all chains) lysoPC: Lysophosphatidylcholines. PC: Phosphatidylcholines. 
SMx:y: Sphingolipids. M0: Baseline. M12: After 12 month of cross-sex hormone treatment.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:37005 | DOI: 10.1038/srep37005
Figure 3. Changes of absolute metabolite concentrations in FtM and MtF following 12 months of CSH. The 
metabolites shown here were identified by randomForest as well as by PCA.
Figure 4. Absolute concentration changes of measured metabolites in FtM and MtF at beginning (0) and 
after 12 months of survey. Cx:y: Acylcarnitines (The abbreviations Cx:y are used to describe the total number 
of carbons and double bonds of all chains). lysoPC: Lysophosphatidylcholines. PC: Phosphatidylcholines. SMx:y: 
Sphingolipids. M0: Baseline. M12: After 12 month of cross-sex hormone treatment.
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increase in the citrulline/arginine ratio37,38. Arginine and citrulline are involved in various metabolic cycles, such 
as the urea cycle, polyamine metabolism and nitric oxide (NO) synthesis32.
As a main function, arginine provides the guanido group in the urea cycle, where it is transformed into orni-
thine during cleavage of urea and finally into citrulline via the reaction with carbamoyl-P39 (Fig. 5). Arginine 
and citrulline are further connected by the arginine-citrulline-cycle, resulting in NO formation39. All enzymes 
necessary to perform the entire urea cycle are exclusively expressed in hepatocytes, while NO synthases (NOS) 
in contrast are found in various other tissues40. The primary sources of NO are endothelial cells41, where NO is 
produced by endothelial NOS (eNOS). As L-Citrulline is the stoichiometric metabolite of NO, the citrulline/
arginine-ratio has been suggested as a surrogate marker to estimate NOS activity in vivo42. This is of particular 
interest, as diminished eNOS activity is involved in arteriosclerosis development43. Although our findings might 
therefore point to an increase in NOS activity in transmen and a decrease in transwomen, it has to be kept in 
mind that there is a debate about the reliability and usefulness of the citrulline/arginine-ratio for assessing whole 
body NOS-activity. This is due to the involvement of these AA in different metabolic pathways and due to the fact 
that only a small amount of plasma arginine turnover, despite its great physiological relevance, actually seems to 
be involved in NO-synthesis44. This is especially true in comparison to the amounts of these AA being involved in 
the urea cycle39. In addition, the finding that there was also a decrease in the ornithine/arginine-ratio, driven by 
a decrease in ornithine levels in transwomen, indicates a decrease in arginase activity which transforms arginine 
into ornithine. In summary, these findings favor the explanation that urea-cycle activity, such as a reduced activity 
in arginase activity, is responsible for treatment–related alterations in our sample (Fig. 5).
ADMA. Furthermore, a significant decrease in asymmetric dimethylarginine (ADMA) in transwomen but no 
corresponding change in transmen was found. ADMA is a methylated derivate of L-arginine. It is generated by 
activity of protein-methyl-transferase enzymes (PRMTs) methylating protein bound arginine. ADMA is detecta-
ble in human blood after being subsequently released into the circulation by proteolysis45.
ADMA is a competitive NO synthase inhibitor45 and it has further been demonstrated that an increased 
ADMA/arginine/-ratio can be a risk marker for arteriosclerosis development46. In the present study, changes 
in ADMA in transwomen are in contrast with changes in the citrulline/arginine-ratio, provided that they are a 
consequence of altered NOS activity. The physiological significance of ADMA as NOS-inhibitor has, however, 
been questioned, as ADMA concentrations under normal circumstances are very low in comparison to those of 
arginine47.
There is evidence of a role played by sex steroids in ADMA regulation. Females in general seem to have lower 
ADMA levels than males48 and estrogen replacement and progestin administration in postmenopausal women is 
followed by ADMA decline49,50,51. Studies have further reported a decrease in ADMA levels in middle aged51 and 
younger hypogonadal men52, increasing again upon the administration of testosterone replacement therapy52. 
CSH therefore seems to have similar effects in transwomen as estrogen replacement in cissexual women and 
similar effects in transmen as testosterone replacement in cissexual men.
There are some limitations in the present study that have to be kept in mind. First, only 14 individuals in the 
transmen group were hormone-naïve at baseline, while the other six had already received Lynestrenol at this 
time point for achieving cessation of the menstrual cycle, which might have influenced metabolic changes as 
well. This was due to the fact that ENIGI is an observational study. Therefore, our influence as regards control of 
treatment modalities was limited to a certain extent. The same applies to the potentially intrinsic effects of CPA 
co-medication in transwomen. In addition, we did not control the cycle phase in the FtM group, which might 
have further compromised the detection of clear hormonal effects. Finally, we cannot exclude the possibility that 
the route of estradiol administration in transwomen might have had an effect on metabolite levels itself. Future 
studies in larger samples should account for such differences.
In conclusion, we are able to show that although CSH brought about several changes in metabolite levels in 
transgender persons, the majority of a priori gender differences persisted throughout treatment. Even though the 
Figure 5. Arginine metabolism. OTC: Ornithin-Transcarbamylase NO: Nitric oxide NOS: Nitric oxide synthase, 
ARG: Arginase, ASL: Argininosuccinate-Lyase, ASS: Argininosuccinate synthetase Table 1.
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sample sizes of our study were relatively small, our data therefore clearly lead to the conclusion that the abun-
dance of reported sex dependent differences in metabolites, under the application of a similar technical setting, is 
not primarily attributable to the sex hormonal milieu but due to other gender-differences.
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